Candriam S.C.A. Buys 50,188 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Candriam S.C.A. lifted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 30.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 214,320 shares of the biopharmaceutical company's stock after purchasing an additional 50,188 shares during the quarter. Candriam S.C.A. owned about 0.20% of Intra-Cellular Therapies worth $17,900,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in Intra-Cellular Therapies by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after buying an additional 2,157 shares during the period. Barclays PLC lifted its holdings in shares of Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock valued at $2,521,000 after acquiring an additional 25,435 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Intra-Cellular Therapies by 31.9% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company's stock worth $33,258,000 after purchasing an additional 109,892 shares during the period. Oak Ridge Investments LLC increased its holdings in Intra-Cellular Therapies by 74.1% in the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock valued at $1,656,000 after purchasing an additional 8,440 shares in the last quarter. Finally, Cynosure Group LLC raised its position in Intra-Cellular Therapies by 161.0% in the third quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company's stock valued at $1,057,000 after purchasing an additional 8,909 shares during the period. Institutional investors and hedge funds own 92.33% of the company's stock.

Remove Ads

Intra-Cellular Therapies Trading Up 0.0 %

ITCI stock traded up $0.01 during midday trading on Monday, reaching $131.25. The company had a trading volume of 2,622,858 shares, compared to its average volume of 1,300,059. The company has a 50 day moving average of $119.20 and a two-hundred day moving average of $93.68. Intra-Cellular Therapies, Inc. has a 1 year low of $63.30 and a 1 year high of $131.39. The company has a market capitalization of $13.96 billion, a P/E ratio of -150.86 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ITCI shares. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Mizuho lowered shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and dropped their price objective for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their target price for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, January 14th. Finally, StockNews.com began coverage on shares of Intra-Cellular Therapies in a research report on Tuesday, March 4th. They issued a "hold" rating for the company. Ten equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.